CDK6 and obesity due to melanocortin 4 receptor deficiency: Our data revealed a previously unknown function of CDK6 in fat metabolism, and suggest that inhibitors of the kinase activity of CDK6 would be beneficial in reversing deleterious effects of metabolic syndromes, and therefore serve as a novel therapeutic target in the treatment of obesity and its related metabolic diseases.